PMID- 36172158 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220930 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 12 DP - 2022 TI - Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. PG - 982948 LID - 10.3389/fonc.2022.982948 [doi] LID - 982948 AB - OBJECTIVES: To compare the safety and efficacy of lenvatinib (LEN) combined with camrelizumab plus transcatheter arterial chemoembolization (TACE-LEN-C) and TACE combined with LEN (TACE-LEN) in patients with unresectable hepatocellular carcinoma (uHCC). METHODS: Eighty-three patients with uHCC treated with TACE-LEN-C or TACE-LEN from September 2018 to May 2021 were enrolled in this retrospective study. Overall survival (OS), progression-free survival (PFS), local tumor response, and adverse events (AEs) were evaluated. Univariate and multivariate analyses were used to determine the factors affecting survival. RESULTS: There were 31 patients in the TACE-LEN-C group and 52 patients in the TACE-LEN group. The median follow-up period was 14.2 months (range 7.2-25.2 months) in the whole study. The combination of triple therapy was found to significantly prolong the PFS (12.5 months vs. 6.6 months, P<0.001) and OS (18.9 months vs. 13.9 months, P<0.001. In terms of tumor response, the combination demonstrated a higher objective response rate (71% vs. 42.3% by the modified Response Evaluation Criteria in Solid Tumors, P=0.023) without a statistically significant difference in the disease control rate (93.5% in TACE-LEN-C, 80.8% in TACE-LEN, P=0.195). In the multivariate analysis, two independent factors affecting PFS were identified: number of tumors and treatment. Three independent factors affected OS: number of tumors, Barcelona Clinic Liver Cancer (BCLC) stage, and treatment. All the AEs were tolerable. CONCLUSION: TACE-LEN-C is a safe and effective treatment for patients with uHCC, and could be a potential treatment option. CI - Copyright (c) 2022 Sun, Zhang, Sun, Ren, Cao, Zhang, Zhu, Guo, Gui, Liu, Chen, Xiong and Zheng. FAU - Sun, Bo AU - Sun B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Lijie AU - Zhang L AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Sun, Tao AU - Sun T AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Ren, Yanqiao AU - Ren Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Cao, Yanyan AU - Cao Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Weihua AU - Zhang W AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhu, Licheng AU - Zhu L AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Guo, Yusheng AU - Guo Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Gui, Yuxi AU - Gui Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Liu, Fengyong AU - Liu F AD - Department of Interventional Radiology, The Fifth Medical Center of Chinese, People's Liberation Army (PLA) General Hospital, Beijing, China. FAU - Chen, Lei AU - Chen L AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Xiong, Fu AU - Xiong F AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zheng, Chuansheng AU - Zheng C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. AD - Key Laboratory of Molecular Imaging of Hubei Province, Wuhan, China. AD - Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article DEP - 20220912 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC9511022 OTO - NOTNLM OT - camrelizumab OT - efficacy OT - hepatocellular carcinoma OT - lenvatinib OT - safety OT - transcatheter arterial chemoembolization COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/09/30 06:00 MHDA- 2022/09/30 06:01 PMCR- 2022/01/01 CRDT- 2022/09/29 02:12 PHST- 2022/06/30 00:00 [received] PHST- 2022/08/17 00:00 [accepted] PHST- 2022/09/29 02:12 [entrez] PHST- 2022/09/30 06:00 [pubmed] PHST- 2022/09/30 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2022.982948 [doi] PST - epublish SO - Front Oncol. 2022 Sep 12;12:982948. doi: 10.3389/fonc.2022.982948. eCollection 2022.